Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Lyme Disease
Interventions
TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
19
States / cities
Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more
Conditions
Blepharitis
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Northridge, California • San Ramon, California + 18 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of TP-05 in Healthy Subjects

NCT05138796
Conditions
Healthy
Interventions
TP-05 (lotilaner oral capsules), Placebo
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Ocular Rosacea
Interventions
lotilaner, Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Houston, Texas • Lynchburg, Virginia
Conditions
Demodex Blepharitis
Interventions
Lotilaner ophthalmic solution, 0.25%, Vehicle control
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Cave Creek, Arizona • Long Beach, California • Colorado Springs, Colorado + 11 more
Conditions
Blepharitis
Interventions
TP-03, 0.25%, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 11 more
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions
Vehicle of TP-03
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Northridge, California • Shelby, North Carolina
Conditions
Healthy Volunteer
Interventions
Low Dose TP-05, High Dose TP-05, Placebo Comparator
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Food Effect of TP-05 in Healthy Participants

NCT05720364
Conditions
Healthy
Interventions
TP-05 (lotilaner oral), fasted group, TP-05 (lotilaner oral), high-fat group, TP-05 (lotilaner oral), low-fat group
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas